Loading…
← CockpitCompetitor Analysis › ETON Eton Pharmaceuticals, Inc.Open in the cockpit ↗

Eton Pharmaceuticals, Inc.ETONCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Makes ready-to-use liquid and sprinkle formulations of existing drugs for pediatric and rare-disease patients.

Momentum leader 100
Mkt cap
$1.79B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$37.0M
20-day average traded
Fwd P/E
24.6×
forward earnings
ROIC−WACC
+48.3 pp
WACC 9.4%
Hurdle
-338 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · USD$61.99
1D-2.6%
1W-9.4%
1M+23.5%
3M+89.2%
6M+225.9%
YTD+266.6%
1Y+253.0%
ATR %6.4%
Beta0.38
52w lowhigh12.2% off high

What Eton Pharmaceuticals does

Makes ready-to-use liquid and sprinkle formulations of existing drugs for pediatric and rare-disease patients.

Takes a drug already proven safe, turns it into a ready-to-use liquid or sprinkle form, and files for approval through the FDA's shortcut for reformulated drugs, which costs far less than developing a new one. It then sells into small rare-disease markets where few rivals bother to compete.

Products and services

  • Alkindi Sprinkle (adrenal insufficiency)
  • Increlex (growth disorder)
  • Other reformulated rare-disease drugs

Customers

  • Pediatric endocrinologists
  • Rare-disease specialists

Where it sits in the supply chain

  • Specialty pharmaceuticals
  • Reformulation of approved drugs
  • Rare-disease/pediatric…

What could go right

  • New product launches/approvals
  • Small-market pricing power

What could go wrong

  • Small addressable markets per product
  • Reliant on continued FDA approvals

Moat: narrow (IP / patents, regulatory licence). FDA approvals for easier-to-dose reformulations create small but defensible orphan niches.

Headquarters: Deer Park, Illinois, US · Founded: 2017 · Employees: 44

Named competitors

Eton Pharmaceuticals at a glance

Size Eton Pharmaceuticals (ETON) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.79B, the 1849th largest of 3,085 United States companies the cockpit tracks. Shares closed at $61.99 on 18 Nov 2026.

Performance Over six months the shares gained 225.9%, against -10.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 100.6% over the last twelve months (peer median +2.7%); the operating margin is 28.9% (peer median 7.5%).

Valuation It trades at 24.6× forward earnings against a peer median of 17.4× (4th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +360%, so the hurdle is -338 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 48.3 points above its cost of capital (9.4% WACC).

Short interest Short interest is 6.9% of the free float (30 Oct 2026).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026ETON 298Peer median 92
Six months, rebased to 100: Eton Pharmaceuticals against the median of its 20 peers (local-currency closes).

Eton Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$141M$80.0M$39.0M$31.6M$21.3M
Revenue growth—+105%+23%+49%—
Gross profit$97.5M$42.7M$23.4M$21.1M$14.3M
EBITDA$45.7M$4.12M-$1.04M-$291,000-$6.50M
Net income$49.9M-$4.60M-$3.82M-$936,000-$9.02M
Free cash flow$38.2M$10.2M$943,000$6.82M$4.78M
Capital expenditure$18.4M$333,000$10.0M$775,000$2.79M
Total debt$24.3M$31.1M$30.0M$5.46M$6.60M

Quarterly statements and history in the cockpit →

Eton Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%60066439339989AGIO301015RAREZYME000028300573DMP000908688166MAZE300723300009ETON6-month return →1-month return →
Up and to the right = strong over both horizons. Eton Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×60066439339989RAREZYME605507300573DMPNATCOPHARM688166COHANCEFAE300723ETONRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Eton Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%6006643933301015688166ETONGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Eton Pharmaceuticals is the large dot.

Eton Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (ETON vs ASND vs AMRX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Eton Pharmaceuticals ETON$1.79B+226%+101%29%24.6×21.9%
Ascendis Pharma A/S ASND$16.9B+12%+94%18%28.0×19.2%
Amneal Pharmaceuticals AMRX$7.62B+79%+9%16%19.2×17.2%

How Eton Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Eton Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureETONPeer medianRank in peer set
1-month return+23.5%-1.0%highest of 21
6-month return+225.9%-10.4%highest of 21
Distance from 52-week high-12.2%-34.4%2nd highest of 21
Revenue growth (TTM)+100.6%+2.7%2nd highest of 21
Operating margin28.9%7.5%3rd highest of 21
Forward P/E24.6×17.4×4th most expensive of 18
Growth the price implies (Req g, 7 yrs)21.9%2.5%2nd most demanding of 15
Growth delivered (Del g)+359.6%+8.1%highest of 15
Hurdle (Req g minus delivered)-337.7 pp-6.4 ppleast demanding of 15
ROIC minus cost of capital+48.3 pp-2.9 pphighest of 21
EV / EBITDA38.5×17.4×3rd most expensive of 7
Net debt / EBITDA-0.7×1.3×2nd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%

Questions

Who are Eton Pharmaceuticals's main competitors?
Named competitors: Ascendis Pharma (ASND), Amneal Pharmaceuticals (AMRX). The cockpit's measured peer set (industry) also includes Harbin Pharmaceutical (600664.SS), United Laboratories International (3933.HK), Shenzhen Hepalink Pharmaceutical (9989.HK), Agios Pharmaceuticals (AGIO), Qingdao Baheal Medical (301015.SZ), Ultragenyx Pharmaceutical (RARE).
Is Eton Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 24.6× against a peer median of 17.4×, 4th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +360%, so the hurdle is -338 pp: the price already allows for a slowdown.
How has Eton Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +225.9% against -10.4% for the median peer; over one year +253.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.